JP2005500368A - Ａｄｈｄ治療用プラミペクソール - Google Patents

Ａｄｈｄ治療用プラミペクソール Download PDF

Info

Publication number: JP2005500368A
Authority: JP; Japan
Prior art keywords: pramipexole; use according; treatment; prevention; propylamino
Prior art date: 2001-08-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2003518529A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005500368A5 (fr

Inventor

ユールゲンレース

フランコボルシニ

Original Assignee

ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-03

Filing date

2002-07-31

Publication date

2005-01-06

2002-07-31 Application filed by ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト filed Critical ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト

2005-01-06 Publication of JP2005500368A publication Critical patent/JP2005500368A/ja

2006-01-05 Publication of JP2005500368A5 publication Critical patent/JP2005500368A5/ja

Status Pending legal-status Critical Current

Links

208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims abstract description 11
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title claims abstract description 11
229960003089 pramipexole Drugs 0.000 title claims description 24
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title claims description 24
230000002265 prevention Effects 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
239000012453 solvate Substances 0.000 claims abstract description 8
FASDKYOPVNHBLU-UHFFFAOYSA-N N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine Chemical compound C1C(NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-UHFFFAOYSA-N 0.000 claims abstract description 7
230000006735 deficit Effects 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
229940025084 amphetamine Drugs 0.000 claims description 4
239000000935 antidepressant agent Substances 0.000 claims description 4
229940005513 antidepressants Drugs 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 3
229910019142 PO4 Inorganic materials 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
229960002430 atomoxetine Drugs 0.000 claims description 3
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229960001344 methylphenidate Drugs 0.000 claims description 3
229960001165 modafinil Drugs 0.000 claims description 3
229960000761 pemoline Drugs 0.000 claims description 3
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
239000010452 phosphate Substances 0.000 claims description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
239000000150 Sympathomimetic Substances 0.000 claims description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
229960001058 bupropion Drugs 0.000 claims description 2
229960003914 desipramine Drugs 0.000 claims description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
229960004801 imipramine Drugs 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
229960001252 methamphetamine Drugs 0.000 claims description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
150000004677 hydrates Chemical class 0.000 abstract description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 2
206010037211 Psychomotor hyperactivity Diseases 0.000 description 10
230000000694 effects Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229950000762 amfetaminil Drugs 0.000 description 2
NFHVTCJKAHYEQN-UHFFFAOYSA-N amfetaminil Chemical compound C=1C=CC=CC=1C(C#N)NC(C)CC1=CC=CC=C1 NFHVTCJKAHYEQN-UHFFFAOYSA-N 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229960002652 pramipexole dihydrochloride Drugs 0.000 description 2
229950010601 pramipexole dihydrochloride monohydrate Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 description 2
238000004448 titration Methods 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000009194 climbing Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
APVQOOKHDZVJEX-QTPLPEIMSA-N pramipexole hydrochloride Chemical compound O.Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-QTPLPEIMSA-N 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
-1 salt monohydrate Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2003518529A 2001-08-03 2002-07-31 Ａｄｈｄ治療用プラミペクソール Pending JP2005500368A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10137633A DE10137633A1 (de)	2001-08-03	2001-08-03	Pramipexol zur Behandlung von ADHD
PCT/EP2002/008500 WO2003013520A1 (fr)	2001-08-03	2002-07-31	Pramipexol destine au traitement de le thada

Publications (2)

Publication Number	Publication Date
JP2005500368A true JP2005500368A (ja)	2005-01-06
JP2005500368A5 JP2005500368A5 (fr)	2006-01-05

Family

ID=7693957

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003518529A Pending JP2005500368A (ja)	2001-08-03	2002-07-31	Ａｄｈｄ治療用プラミペクソール

Country Status (8)

Country	Link
EP (1)	EP1416930A1 (fr)
JP (1)	JP2005500368A (fr)
AR (1)	AR035273A1 (fr)
CA (1)	CA2453485A1 (fr)
DE (1)	DE10137633A1 (fr)
MX (1)	MXPA04001001A (fr)
UY (1)	UY27408A1 (fr)
WO (1)	WO2003013520A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200906997A1 (tr)	2009-09-11	2011-03-21	Sanovel �La� San. Ve T�C. A. �.	Pramipeksol farmasötik bileşimleri.
TR200907554A1 (tr) *	2009-10-06	2011-04-21	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Oral yolla dağılan pramıpexole bileşimleri.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5621133A (en) *	1989-05-31	1997-04-15	Deninno; Michael P.	Dopamine agonists
WO2001089453A2 (fr) *	2000-05-19	2001-11-29	Wayne State University	Derive des 2-aminotetralines et leurs analogues pharmacologiques presentant une activite et un comportement de recepteur du systeme nerveux central differentiels
US20020016334A1 (en) *	2000-07-31	2002-02-07	Coe Jotham Wadsworth	Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US6613308B2 (en) *	2000-09-19	2003-09-02	Advanced Inhalation Research, Inc.	Pulmonary delivery in treating disorders of the central nervous system

2001
- 2001-08-03 DE DE10137633A patent/DE10137633A1/de not_active Withdrawn
2002
- 2002-07-31 CA CA002453485A patent/CA2453485A1/fr not_active Abandoned
- 2002-07-31 JP JP2003518529A patent/JP2005500368A/ja active Pending
- 2002-07-31 EP EP02762417A patent/EP1416930A1/fr not_active Withdrawn
- 2002-07-31 MX MXPA04001001A patent/MXPA04001001A/es not_active Application Discontinuation
- 2002-07-31 WO PCT/EP2002/008500 patent/WO2003013520A1/fr not_active Ceased
- 2002-08-02 UY UY27408A patent/UY27408A1/es not_active Application Discontinuation
- 2002-08-02 AR ARP020102946A patent/AR035273A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR035273A1 (es)	2004-05-05
WO2003013520A1 (fr)	2003-02-20
EP1416930A1 (fr)	2004-05-12
CA2453485A1 (fr)	2003-02-20
UY27408A1 (es)	2003-02-28
DE10137633A1 (de)	2003-02-20
MXPA04001001A (es)	2004-04-20

Publication	Publication Date	Title
CN100528151C (zh)	2009-08-19	莫达非尼药物剂型
US20120225901A1 (en)	2012-09-06	Dosage form containing oxycodone and naloxone
HU227306B1 (en)	2011-03-28	Use of tomoxetin for the production of medicaments against attention-deficit/hyperactivity disorder
US11266633B2 (en)	2022-03-08	NK-1 antagonist compositions and methods for use in treating depression
CN1252722A (zh)	2000-05-10	脱羰乙氧氯雷他定在治疗尿失禁、晕动病和眩晕药剂的制备中的应用
US20080146628A1 (en)	2008-06-19	Pramipexole for the treatment of adhd
Safdieh et al.	2006	A case of hyponatremia induced by duloxetine
EP1423104A1 (fr)	2004-06-02	Polytherapie servant au traitement de troubles neurologiques
JP2005500368A (ja)	2005-01-06	Ａｄｈｄ治療用プラミペクソール
JP2001510800A (ja)	2001-08-07	注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
JP2002020291A (ja)	2002-01-23	認知機能障害の治療剤
JP2007519646A (ja)	2007-07-19	体重の持続的低減のための化合物
US20080108597A1 (en)	2008-05-08	New Use of Quetiapine
JPH022861B2 (fr)	1990-01-19
Mahmoud et al.	2022	Tramadol as an analgesic
US6281248B1 (en)	2001-08-28	Composition for treating asthma
CN1671368A (zh)	2005-09-21	疼痛继发性抑郁（dsp）的治疗
JP2005500368A5 (fr)	2006-01-05
JP2002521433A (ja)	2002-07-16	モクロベマイドを用いる、ある種の精神医学的および医学的異常の処置と予防の方法および組成物
JP2005500367A (ja)	2005-01-06	抗痙攣剤としてのプラミペクソール
WO2025218751A1 (fr)	2025-10-23	Utilisation d'une composition dans la préparation d'un médicament
Ellison et al.	2008	Pharmacotherapy of late-life depression: evidence-based recommendations
Standard et al.	2016	Pr ATOMOXETINE
HK40071665B (zh)	2024-10-04	在痴呆患者中治疗行为和精神症状
Standard	2016	PrTEVA-ATOMOXETINE

Legal Events

Date	Code	Title	Description
2005-08-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050801
2005-08-02	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050801
2009-05-26	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090525
2009-11-10	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091109